Published in Br J Haematol on June 01, 2002
Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res (2009) 1.35
Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: case report. BMC Cancer (2004) 1.26
KIT as a therapeutic target in melanoma. J Invest Dermatol (2010) 0.97
Central nervous system blast crisis in chronic myeloid leukemia on imatinib mesylate therapy: report of two cases. Indian J Hematol Blood Transfus (2011) 0.92
Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk (2011) 0.91
Cancer treatment with kinase inhibitors: what have we learnt from imatinib? Br J Cancer (2004) 0.90
Brain metastasis from gastrointestinal stromal tumor: a case report and review of the literature. Case Rep Gastroenterol (2011) 0.88
Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leuk Lymphoma (2013) 0.85
Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform. Wien Klin Wochenschr (2008) 0.80
Sunitinib treatment for multiple brain metastases from jejunal gastrointestinal stromal tumor: case report. Neurol Med Chir (Tokyo) (2013) 0.77
Metastatic cerebellar gastrointestinal stromal tumor with obstructive hydrocephalus arising from the small intestine: a case report and review of the literature. Case Rep Oncol Med (2014) 0.75
Blast phase transformation of chronic myelogenous leukemia presenting with central nervous system manifestation. Asian J Neurosurg (2016) 0.75
Dasatinib as the salvage therapy for chronic myeloid leukemia with blast crisis and central nervous system involvement: A case report. Oncol Lett (2015) 0.75
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med (2006) 8.12
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med (2009) 5.81
Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord (2004) 4.83
Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med (2004) 4.56
A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet (2011) 4.52
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res (2005) 4.02
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Early consolidation in human primary motor cortex. Nature (2002) 3.56
SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol (2009) 3.55
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol (2004) 3.51
Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48
Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res (2003) 3.44
Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]. Lancet Neurol (2010) 3.15
BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet (2002) 3.10
Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord (2004) 2.90
Minimal clinically important change on the unified Parkinson's disease rating scale. Mov Disord (2006) 2.81
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol (2013) 2.65
Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2007) 2.62
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res (2006) 2.44
Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood (2002) 2.37
Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord (2010) 2.34
Neurological outcome of septic cardioembolic stroke after infective endocarditis. Stroke (2006) 2.31
Mortality in Parkinson's disease: a 20-year follow-up study. Mov Disord (2009) 2.28
Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2008) 2.28
Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2010) 2.26
Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med (2006) 2.26
Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res (2008) 2.22
High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat (2004) 2.14
Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord (2004) 2.13
Seminar on choreas. Lancet Neurol (2006) 2.09
Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation (2004) 2.08
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord (2011) 2.05
Multiple system atrophy. Lancet Neurol (2004) 2.04
Levodopa: 50 years of a revolutionary drug for Parkinson disease. Mov Disord (2014) 1.99
Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet (2002) 1.98
The diagnosis of Parkinson's disease. Lancet Neurol (2006) 1.97
Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord (2007) 1.96
Pallidal deep brain stimulation in patients with primary generalised or segmental dystonia: 5-year follow-up of a randomised trial. Lancet Neurol (2012) 1.93
Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther (2003) 1.93
Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol (2005) 1.88
Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol (2007) 1.84
Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2008) 1.83
CD4+CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice. J Am Soc Nephrol (2005) 1.83
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol (2013) 1.82
PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet (2008) 1.78
Deep brain stimulation: preoperative issues. Mov Disord (2006) 1.77
Striatal transplantation for multiple system atrophy--are grafts affected by alpha-synucleinopathy? Exp Neurol (2009) 1.77
Red flags for multiple system atrophy. Mov Disord (2008) 1.75
Multiple system atrophy: a primary oligodendrogliopathy. Ann Neurol (2008) 1.72
Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord (2008) 1.71
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord (2011) 1.70
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol (2006) 1.69
Do guidelines matter? Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines' criteria. Am J Gastroenterol (2006) 1.68
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol (2011) 1.68
Normative EMG values during REM sleep for the diagnosis of REM sleep behavior disorder. Sleep (2012) 1.68
The effect of zoledronic acid on the function and differentiation of myeloid cells. Haematologica (2006) 1.66
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord (2005) 1.65
Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp Neurol (2007) 1.65
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol (2007) 1.63
Cognitive, extrapyramidal, and magnetic resonance imaging predictors of functional impairment in nondemented older community dwellers: the Sydney Older Person Study. J Am Geriatr Soc (2006) 1.63
Migration and transmission of blood-borne infections among injection drug users: understanding the epidemiologic bridge. Drug Alcohol Depend (2007) 1.60
Costs of illness and care in Parkinson's disease: an evaluation in six countries. Eur Neuropsychopharmacol (2011) 1.60
Prevalence of movement disorders in men and women aged 50-89 years (Bruneck Study cohort): a population-based study. Lancet Neurol (2005) 1.60
Short-term outcomes after brief ambulatory opioid detoxification with buprenorphine in young heroin users. Addiction (2003) 1.58
Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol (2013) 1.56
Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease. Brain (2013) 1.54
Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease. Neuroimage (2004) 1.51
Restless legs syndrome in Parkinson's disease. Mov Disord (2009) 1.51
Quantification of electromyographic activity during REM sleep in multiple muscles in REM sleep behavior disorder. Sleep (2008) 1.49
Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). Mov Disord (2006) 1.49
Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res (2004) 1.46
EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J Clin Pathol (2011) 1.46
Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood (2002) 1.45
Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease. Mov Disord (2013) 1.44
Myelodysplastic/myeloproliferative disease with erythropoietic hyperplasia (erythroid preleukemia) and the unique translocation (8;9)(p23;p24): first description of a case. Hum Pathol (2005) 1.43
Polymorphisms in the glial glutamate transporter SLC1A2 are associated with essential tremor. Neurology (2012) 1.41
Defining at-risk populations for Parkinson's disease: lessons from ongoing studies. Mov Disord (2012) 1.41
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord (2013) 1.41
Child safety in cars. BMJ (2006) 1.39
GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib. Blood (2009) 1.37
Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am J Pathol (2005) 1.36
Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy. Mov Disord (2007) 1.35
Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord (2010) 1.34
White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: a diffusion-tensor imaging and voxel-based morphometry study. Ann Neurol (2010) 1.34
Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia. Glia (2012) 1.32
d4eBP acts downstream of both dTOR and dFoxo to modulate cardiac functional aging in Drosophila. Aging Cell (2009) 1.31
Health-related quality-of-life scales in Parkinson's disease: critique and recommendations. Mov Disord (2011) 1.31
O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med (2011) 1.30
Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells. Immunobiology (2003) 1.30
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol (2007) 1.29
Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. Mov Disord (2012) 1.28